Back to Search
Start Over
FDA Grants Priority Review for Eagle Pharmaceuticals' Ryanodex NDA for the Treatment of Exertional Heat Stroke
- Source :
- Business Wire. March 27, 2017
- Publication Year :
- 2017
-
Abstract
- -PDUFA Date of July 23, 2017- WOODCLIFF LAKE, N.J. -- Eagle Pharmaceuticals (Nasdaq:EGRX) ('Eagle' or 'the Company') announced today that their 505(b)(2) New Drug Application (NDA) for Ryanodex[R] (dantrolene sodium) [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Business Wire
- Publication Type :
- News
- Accession number :
- edsgcl.487270763